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Aim: The aim of this report is to provide initial evidence that add-on treatmentwith perampanel might be highly
effective in progressive myoclonic epilepsy such as Lafora disease.
Case report: We report on a 21-year-old woman suffering from persistent myoclonus and generalized tonic–
clonic seizures for more than seven years. Additionally, ataxia, a disturbance in speech and gait, as well as a cog-
nitive declinewere rapidly progressing. Subsequently, the diagnosis of Lafora diseasewas conﬁrmed by the iden-
tiﬁcation of a novel homozygous missense mutation in exon 3 of the EPM2A gene (c.538CNG; p.L180V).
Adjunctive therapywith perampanelwas started in this patientwith advanced Lafora disease andwas titratedup
to 8 mg/day. A sustained and reproducible remission ofmyoclonus andGTCS could be achieved for a follow-up of
three months. After dosage reduction to 6 mg/day, seizures recurred; however, on increasing the daily dose to
10 mg, seizures stopped for another three months. The patient also regained her ability to walk with help and
the aid of a walker.
Conclusions: Perampanel is a selective, noncompetitive antagonist of AMPA-type glutamate receptors and recently
licensed as adjunctive therapy for the treatment of refractory focal onset seizures. There is evidence for its effec-
tiveness in generalized epilepsies, and phase III studies for this indication are on the way. Our case illustrates
the possibility that perampanel might be a valuable option for treatment in PME. Considering its impressive
efﬁcacy in this case, we suggest a prospective, multicenter study evaluating perampanel in PME.© 2013 The Authors. Published by Elsevier Inc.Open access under CC BY-NC-ND license.1. Introduction
The treatment of patients with Lafora disease (LD), a form of progres-
sive myoclonus epilepsies (PME), proves to be very difﬁcult, and previ-
ously healthy children or teenagers are afﬂicted with ever-worsening
and soon-intractable myoclonus and epilepsy, which are usually asso-
ciated with dementia and early death [1,2].
Lafora disease is an autosomal recessive, most commonly teenage-
onset neurodegenerative disorder caused by mutations in either the
EPM2A or NHLRC1 gene, encoding the interacting proteins laforin and
malin, respectively. Patients with LD usually present between 8 and
18 years of agewith an insidious near-simultaneous or closely consecu-
tive appearance of headaches, difﬁculties in school work, myoclonus,
generalized tonic–clonic seizures (GTCS), and visual hallucinations ofy and Epilepsy Center Hessen,
Marburg, Germany. Fax: +49
(A. Strzelczyk).
.Open access under CC BY-NC-ND liceboth epileptic and psychotic origin. For many years, patients struggle
to maintain normal contact and communication, interrupted by ex-
tremely frequent myoclonic absence seizures. Gradually, dementia
sets in, and patients are in an almost continuous myoclonus with
absences, frequent GTCS, and profound dementia or vegetative state
within a decade of onset [1–3].
We report a case in which perampanel was started in an adult pa-
tient with advanced LD leading to sustained remission in myoclonus
and generalized tonic–clonic seizures.
2. Case report
A 14-year-old, normally developed girl of Turkish descent initially
presented to our clinic with myoclonus and GTCS. During video-EEG
monitoring, interictal generalized spikes and polyspikes as well as
three seizures with generalized onset were recorded. There was no
evidence of focal EEG seizure onset. Over the next 7 years, no seizure re-
mission had been achieved on various combinations of antiepileptic
drugs or treatment with vagus nerve stimulation. Follow-up at the age
of 18 years showed mild generalized and hippocampal atrophy on
MRI (Fig. 1A–D). Neuropsychological evaluation showed a decline in
language skills, especially in German, her second language. The patientnse.
Fig. 1. T1, T2, and FLAIR MRI with mild generalized atrophy (A, B) as well as bilateral hippocampal atrophy (C, D).
Fig. 2. EEG with generalized epileptiform discharges and associated myoclonus before initiation of perampanel.
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Table 1
Antiepileptic therapy and serum concentrations during seizure remission.
Anticonvulsant Daily dose Serum concentration Therapeutic level
Clonazepam 12 mg n.a. n.a.
Levetiracetam 4000 mg 22.3 mg/l 3–34 mg/l
Perampanel 8 mg 442 μg/l 100–800 μg/l
Piracetam 12,000 mg 52 μg/ml n.a.
Valproate 1350 mg 69.8 μg/ml 40–100 μg/ml
Zonisamide 600 mg 21.6 μg/ml 10–40 μg/ml
Ketogenic diet 4:1 ratio
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at a special school had decreased because of the seizures. No standard-
ized neuropsychological testing was possible. The patient could name
colors correctly and was interested in details of shown pictures. We
observed a decline in language skills and attention, but motivational
skills remained as a cognitive resource. Since then, disturbance in gait
(ataxia) and cognitive declinewere rapidly progressing, and eventually,
the patient lost her ability to speak.
The suspected diagnosis of Lafora disease was conﬁrmed by the
identiﬁcation of a novel homozygous missense mutation in exon 3 of
the EPM2A gene (c.538CNG; p.L180V) by Sanger sequencing, which
was heterozygous in her unaffected parents.
InApril 2012, the 21-year-old patientwas admittedwith a generalized
convulsive status epilepticus (SE) that proved super-refractory [4]. Ther-
apy with thiopental anesthesia, steroids, and magnesium did not control
the SE, and a termination of all therapy was considered. Finally, initiation
andmaintenance of a ketogenic diet terminated the SE, as reported earlier
[5], and the patient was discharged. She was bedbound and continued to
suffer from daily myoclonus and frequent GTCS every 3–4 days despite
antiepileptic polytherapywith high doses of valproate, levetiracetam, clo-
nazepam, piracetam, and zonisamide and ketogenic diet.
Subsequently, the patient was admitted in September 2012 because
of seizure exacerbation caused by infection and ﬂuoroquinolone antibi-
otic therapy. The EEG showed generalized epileptiform discharges and
frequent myoclonus (Fig. 2). The patient was started on an adjunctiveFig. 3. EEG with bifrontal polyspikes andtherapy with the newly licensed perampanel, which was quickly
titrated up to 8 mg/daywithin oneweek. No side effectswere observed.
The other anticonvulsant agents, such as valproate (1350 mg/day),
levetiracetam (4000 mg/day), zonisamide (600 mg/day), clonazepam
(12 mg/day), piracetam (12,000 mg/day), and the ketogenic diet (4:1
ratio) were not changed at this point in time. The GTCS stopped, and
the patientwas discharged. On follow-up fourmonths later, the parents
reported sustained seizure remission without myoclonus and GTCS
for more than 3 months on an unchanged therapeutic regimen (see
Table 1). The EEG showed less epileptiform discharges (Fig. 3). The
patient was able to walk with help and the aid of a walker and could
climb a few stairs during physiotherapy. A few weeks later, the parents
reported gait problems, and therefore, perampanel was decreased from
8 mg/day to 6 mg/day. Generalized tonic–clonic seizures recurred, but
control was again achieved after increasing perampanel to 10 mg/day
with a follow-up of another three months.
3. Discussion
Perampanel was used off-label in this patient with advanced LD and
resulted in a sustained and reproducible remission of myoclonus and
GTCS. Transient dose reduction of perampanel caused the reoccurrence
of seizures, proving the causal relationship of therapy with perampanel
and seizure freedom in this progressive disorder.
Perampanel is a selective, noncompetitive antagonist of AMPA-type
glutamate receptors and was recently licensed as adjunctive therapy
for the treatment of refractory focal onset seizures [6–8]. Perampanel
exhibited broad-spectrum efﬁcacy in various animal seizure models,
and there is evidence for its effectiveness in generalized epilepsies
[9]. A phase 3 trial to determine the efﬁcacy and safety of adjunctive
perampanel in primary GTCS is currently recruiting patients
(ClinicalTrials.gov identiﬁer: NCT01393743). The reason for the striking
efﬁcacy in our patient with LD remains elusive and requires further
study.
New treatment options are desired in PME such as LD and
Unverricht–Lundborg disease [1,2] to improve daily functioning andgeneralized slowing on follow-up.
121K. Schorlemmer et al. / Epilepsy & Behavior Case Reports 1 (2013) 118–121seizure control. Our case illustrates that perampanelmight be a valuable
option for treatment in PME. Considering its impressive efﬁcacy in
this case, we suggest a prospective, multicenter study evaluating
perampanel in PME.
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